Studies have indicated that the co-delivery of chemotherapeutic drugs using uPAR-targeted nanoparticles enhanced the therapeutic efficacy in triple negative breast cancer and pancreatic cancer animal tumor models. The gene discussed is PLAUR; the disease is triple-negative breast carcinoma.